Article

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: Implications for sequence of pathological events in Alzheimers disease

Clifford R. Jack, Mayo Clinic, Diagnostic Radiology, 200 First Street SW, Rochester, MN 55905, USA. .
Brain (Impact Factor: 10.23). 03/2009; 132(Pt 5):1355-65. DOI: 10.1093/brain/awp062
Source: PubMed

ABSTRACT The purpose of this study was to use serial imaging to gain insight into the sequence of pathologic events in Alzheimer's disease, and the clinical features associated with this sequence. We measured change in amyloid deposition over time using serial (11)C Pittsburgh compound B (PIB) positron emission tomography and progression of neurodegeneration using serial structural magnetic resonance imaging. We studied 21 healthy cognitively normal subjects, 32 with amnestic mild cognitive impairment and 8 with Alzheimer's disease. Subjects were drawn from two sources--ongoing longitudinal registries at Mayo Clinic, and the Alzheimer's disease Neuroimaging Initiative (ADNI). All subjects underwent clinical assessments, MRI and PIB studies at two time points, approximately one year apart. PIB retention was quantified in global cortical to cerebellar ratio units and brain atrophy in units of cm(3) by measuring ventricular expansion. The annual change in global PIB retention did not differ by clinical group (P = 0.90), and although small (median 0.042 ratio units/year overall) was greater than zero among all subjects (P < 0.001). Ventricular expansion rates differed by clinical group (P < 0.001) and increased in the following order: cognitively normal (1.3 cm(3)/year) < amnestic mild cognitive impairment (2.5 cm(3)/year) < Alzheimer's disease (7.7 cm(3)/year). Among all subjects there was no correlation between PIB change and concurrent change on CDR-SB (r = -0.01, P = 0.97) but some evidence of a weak correlation with MMSE (r =-0.22, P = 0.09). In contrast, greater rates of ventricular expansion were clearly correlated with worsening concurrent change on CDR-SB (r = 0.42, P < 0.01) and MMSE (r =-0.52, P < 0.01). Our data are consistent with a model of typical late onset Alzheimer's disease that has two main features: (i) dissociation between the rate of amyloid deposition and the rate of neurodegeneration late in life, with amyloid deposition proceeding at a constant slow rate while neurodegeneration accelerates and (ii) clinical symptoms are coupled to neurodegeneration not amyloid deposition. Significant plaque deposition occurs prior to clinical decline. The presence of brain amyloidosis alone is not sufficient to produce cognitive decline, rather, the neurodegenerative component of Alzheimer's disease pathology is the direct substrate of cognitive impairment and the rate of cognitive decline is driven by the rate of neurodegeneration. Neurodegeneration (atrophy on MRI) both precedes and parallels cognitive decline. This model implies a complimentary role for MRI and PIB imaging in Alzheimer's disease, with each reflecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration.

Download full-text

Full-text

Available from: Maria Shiung, Aug 14, 2015
2 Followers
 · 
162 Views
  • Source
    • "In this way, experiments employing the most suitable animal model could be designed to measure similar, or ideally exact, endpoints/outcomes that are used in patients, for the most reliable predictions to be made. This has been adopted in certain respects, with the use of characterized biomarkers between patients and animal models for studying neurodegeneration (Delatour, Guegan, Volk, & Dhenain, 2006; Jack et al., 2009), such as in PD with in vivo SPECT imaging measurement of [99mTc]-TRODAT-1 binding (Fernagut et al., 2010; Meissner et al., 2003; Prunier et al., 2003), or in AD research, with levels of amyloid-b and phosphorylated tau proteins in the CSF (Buerger et al., 2006; Hampel et al., 2004; Head et al., 2010; Zilka, Korenova, Kovacech, Iqbal, & Novak, 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although everyone would agree that successful translation of therapeutic candidates for central nervous disorders should involve non-human primate (nhp) models of cognitive disorders, we are left with the paucity of publications reporting either the target validation or the actual preclinical testing in heuristic nhp models. In this review, we discuss the importance of nhps in translational research, highlighting the advances in technological/ methodological approaches for 'bridging the gap' between preclinical and clinical experiments. In this process, we acknowledge that nhps remain a vital tool for the investigation of complex cognitive functions, given their resemblance to humans in aspects of behaviour, anatomy and physiology. The recent improvements made for a suitable nhp model in cognitive research, including new surrogates of disease and application of innovative methodological approaches, are continuous strides for reaching efficient translation for human benefit. This will ultimately aid the development of innovative treatments against the current and future threat of neurological and psychiatric disorders to the global population. Copyright © 2015. Published by Elsevier Inc.
    Neurobiology of Learning and Memory 06/2015; DOI:10.1016/j.nlm.2015.06.012 · 4.04 Impact Factor
  • Source
    • "Since the subject's morphometric information is already built into the estimate of b via Equation 6, our result might simply imply that CSF biomarkers lack incremental power to predict rate of progression, beyond what is explained by imaging. This is in line with converging understanding based on the early deposition and subsequent plateauing of amyloid (Villemagne et al., 2013), that while CSF biomarkers are good predictors of conversion risk, neurodegenerative markers like MRI are more sensitive predictors of current disease state and its rate of decline (Da et al., 2014; Dickerson and Wolk, 2013; Fjell and Walhovd, 2011; Jack et al., 2009; Vemuri et al., 2009). Our dichotomized CSF results support this interpretation, such that CSF biomarker levels appear to exert an effect on rate of progression only beyond the pathologic threshold (Fjell et al., 2010; Mattsson et al., 2014; Schott et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer’s disease (AD) is an amyloid-facilitated tauopathy (Braak et al., 2000) whose origin and subsequent advance within the brain is well characterized: the disease begins in the mesial temporal lobe, an event accompanied by the accumulation of misfolded β-amyloid and tau proteins, and thence progresses along fiber pathways. Histopathological evidence of this highly stereotyped progression has come to be known as the Braak model (Braak and Braak, 1996): neurofibrillary tau tangles are first found in entorhinal cortex and hippocampus (stages I–II), then spread into the amygdala and basolateral temporal lobe (stages III–IV), followed by isocortical association areas (stages V–VI). Morphological changes accompanying this pathological progression are clearly visible on MRI, especially from cross-sectional and longitudinal morphometric mapping (Fischl et al., 2002, Klauschen et al., 2009, Smith et al., 2004 and Wu et al., 2007). Longitudinal studies (Apostolova and Thompson, 2008, Apostolova et al., 2007, Thompson et al., 2003 and Whitwell et al., 2007) confirm that progression follows vulnerable fiber pathways rather than spatial proximity (Englund et al., 1988, Kuczynski et al., 2010 and Villain et al., 2008), closely mirroring Braak pathological stages (Whitwell et al., 2007).
    Cell Reports 01/2015; 46(3). DOI:10.1016/j.celrep.2014.12.034 · 8.36 Impact Factor
  • Source
    • "It is also important to investigate if and how neuroimaging measures might relate to cognitive decline. Studies have reported dissociations between amyloid deposition and cognitive decline in healthy controls and subjects with MCI and AD (Jack et al., 2009) while others have found associations between amyloid burden and poorer cognitive performance (Kennedy et al., 2012; Rodrigue et al., 2012) and even changing associations based on the disease stage (Chetelat, 2013; Jack et al., 2009; Naslund et al., 2000; Villemagne et al., 2013). The potential predictive power of DTI on cognition has been less explored, but there is evidence that DTI values correlate with decline in working memory in healthy elderly (Bendlin et al., 2010a; Charlton et al., 2006; Pfefferbaum et al., 2000; Raz et al., 2010), and significant correlations between measures of white matter and AD symptom severity have been found, suggesting that A C C E P T E D M A N U S C R I P T "
    [Show abstract] [Hide abstract]
    ABSTRACT: Some cognitively healthy individuals develop brain amyloid accumulation, suggestive of incipient Alzheimer's disease (AD), but the effect of amyloid on other potentially informative imaging modalities, such as Diffusion Tensor Imaging (DTI), in characterizing brain changes in preclinical AD requires further exploration. In this study, a sample (N = 139, mean age 60.6, range 46 to 71) from the Wisconsin Registry for Alzheimer's Prevention (WRAP), a cohort enriched for AD risk factors, was recruited for a multimodal imaging investigation that included DTI and [C-11]Pittsburgh Compound B (PiB) positron emission tomography (PET). Participants were grouped as amyloid positive (Aβ+), amyloid indeterminate (Aβi), or amyloid negative (Aβ-) based on the amount and pattern of amyloid deposition. Regional voxel-wise analyses of four DTI metrics, fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (Da), and radial diffusivity (Dr), were performed based on amyloid grouping. Three regions of interest (ROIs), the cingulum adjacent to the corpus callosum, hippocampal cingulum, and lateral fornix, were selected based on their involvement in the early stages of AD. Voxel-wise analysis revealed higher FA among Aβ+ compared to Aβ- in all three ROIs and in Aβi compared to Aβ- in the cingulum adjacent to the corpus callosum. Follow-up exploratory whole-brain analyses were consistent with the ROI findings, revealing multiple regions where higher FA was associated with greater amyloid. Lower fronto-lateral gray matter MD was associated with higher amyloid burden. Further investigation showed a negative correlation between MD and PiB signal, suggesting that Aβ accumulation impairs diffusion. Interestingly, these findings in a largely presymptomatic sample are in contradistinction to relationships reported in the literature in symptomatic disease stages of Mild Cognitive Impairment and AD, which usually show higher MD and lower FA. Together with analyses showing that cognitive function in these participants is not associated with any of the four DTI metrics, the present results suggest an early relationship between PiB and DTI, which may be a meaningful indicator of the initiating or compensatory mechanisms of AD prior to cognitive decline.
    12/2014; 4. DOI:10.1016/j.nicl.2014.02.001
Show more